FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2285004129> ?p ?o ?g. }

• W2285004129 endingPage "241" @default.
• W2285004129 startingPage "241" @default.
• W2285004129 abstract "241 Background: The timing and sequencing of combination therapy is becoming of outmost importance for the treatment of mCRPC patients. As a result our hypothesis has been to layer on enzalutamide very quickly after the completion of sipuleucel-T. Methods: We collected the data of 84 patients with chemo-naïve mCRPC treated with sipuleucel-T at our practice from September 2011 to January 2014. Prior to the initiation of treatment the baseline status was recorded in all patients. We then selected and analyzed outcomes of 19 patients who received sequential enzalutamide treatment after completion of sipuleucel-T. The average timing for the initiation of enzalutamide was 2.5±1.6 months after completion of the immune therapy. We believe this to be a very unique cohort as all of these patients were treated with enzalutamide off label (i.e. pre-chemo). Results: The median time of enzalutamide therapy was 5.4 months (range: 1-13). In our cohort of 19 patients: 1 case showed radiographic full regression of metastatic lesions in bone, lung and lymph nodes. Another case showed radiographic full regression of bony metastatic lesions. 2 other cases – showed a partial regression radiographically of bony metastatic disease. 13 cases showed stable disease according to RECIST-criteria. The remaining 2 patients were deceased due to progression of mCRPC. The patients with full and partial response were in the lowest quartile of our cohort as defined as a PSA ≤ 3.87 ng/ml. On the contrary, all cases of progression and death were documented in highest (last) quartile as defined by a PSA level more than 84 ng/ml. Conclusions: Our experience demonstrates a promising effect using sequential sipuleucel-T immunotherapy followed by enzalutamide for mCRPC. To our knowledge this will be the first case of complete radiographic regression of lung, bone, and extensive lymph node disease. Currently there are studies undergoing that will hopefully validate our experience with using enzalutamide at the initiation of sipuleucel-T." @default.
• W2285004129 created "2016-06-24" @default.
• W2285004129 creator A5002373327 @default.
• W2285004129 creator A5004625882 @default.
• W2285004129 creator A5009538857 @default.
• W2285004129 creator A5016944058 @default.
• W2285004129 date "2015-03-01" @default.
• W2285004129 modified "2023-09-27" @default.
• W2285004129 title "Effect of combined sequential treatment of sipuleucel-T followed by enzalutamide in metastatic chemo-naïve castration-resistant prostate cancer: Results of single center of large urology group." @default.
• W2285004129 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.241" @default.
• W2285004129 hasPublicationYear "2015" @default.
• W2285004129 type Work @default.
• W2285004129 sameAs 2285004129 @default.
• W2285004129 citedByCount "1" @default.
• W2285004129 countsByYear W22850041292015 @default.
• W2285004129 crossrefType "journal-article" @default.
• W2285004129 hasAuthorship W2285004129A5002373327 @default.
• W2285004129 hasAuthorship W2285004129A5004625882 @default.
• W2285004129 hasAuthorship W2285004129A5009538857 @default.
• W2285004129 hasAuthorship W2285004129A5016944058 @default.
• W2285004129 hasConcept C121608353 @default.
• W2285004129 hasConcept C126322002 @default.
• W2285004129 hasConcept C126894567 @default.
• W2285004129 hasConcept C141071460 @default.
• W2285004129 hasConcept C143998085 @default.
• W2285004129 hasConcept C2776551883 @default.
• W2285004129 hasConcept C2780192828 @default.
• W2285004129 hasConcept C44249647 @default.
• W2285004129 hasConcept C61367390 @default.
• W2285004129 hasConcept C68443243 @default.
• W2285004129 hasConcept C71924100 @default.
• W2285004129 hasConcept C72563966 @default.
• W2285004129 hasConceptScore W2285004129C121608353 @default.
• W2285004129 hasConceptScore W2285004129C126322002 @default.
• W2285004129 hasConceptScore W2285004129C126894567 @default.
• W2285004129 hasConceptScore W2285004129C141071460 @default.
• W2285004129 hasConceptScore W2285004129C143998085 @default.
• W2285004129 hasConceptScore W2285004129C2776551883 @default.
• W2285004129 hasConceptScore W2285004129C2780192828 @default.
• W2285004129 hasConceptScore W2285004129C44249647 @default.
• W2285004129 hasConceptScore W2285004129C61367390 @default.
• W2285004129 hasConceptScore W2285004129C68443243 @default.
• W2285004129 hasConceptScore W2285004129C71924100 @default.
• W2285004129 hasConceptScore W2285004129C72563966 @default.
• W2285004129 hasIssue "7_suppl" @default.
• W2285004129 hasLocation W22850041291 @default.
• W2285004129 hasOpenAccess W2285004129 @default.
• W2285004129 hasPrimaryLocation W22850041291 @default.
• W2285004129 hasRelatedWork W1652439388 @default.
• W2285004129 hasRelatedWork W2309274182 @default.
• W2285004129 hasRelatedWork W2414042649 @default.
• W2285004129 hasRelatedWork W2590294003 @default.
• W2285004129 hasRelatedWork W2929753048 @default.
• W2285004129 hasRelatedWork W2971490708 @default.
• W2285004129 hasRelatedWork W3023947295 @default.
• W2285004129 hasRelatedWork W3132581442 @default.
• W2285004129 hasRelatedWork W3197069188 @default.
• W2285004129 hasRelatedWork W4229076799 @default.
• W2285004129 hasVolume "33" @default.
• W2285004129 isParatext "false" @default.
• W2285004129 isRetracted "false" @default.
• W2285004129 magId "2285004129" @default.
• W2285004129 workType "article" @default.